Compare NWGL & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NWGL | OSRH |
|---|---|---|
| Founded | 2008 | N/A |
| Country | Macau | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.6M | 18.4M |
| IPO Year | 2022 | N/A |
| Metric | NWGL | OSRH |
|---|---|---|
| Price | $1.09 | $0.47 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 37.2K | ★ 387.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.91 | $0.38 |
| 52 Week High | $6.61 | $4.33 |
| Indicator | NWGL | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 34.84 | 46.42 |
| Support Level | $0.97 | $0.39 |
| Resistance Level | $1.12 | $0.74 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 13.89 | 43.08 |
CL Workshop Group Ltd, formerly Nature Wood Group Ltd is a vertically-integrated forestry company that focuses on FSC business operations. It produces various products, including logs, decking, flooring, sawn timber, recycled charcoal, synthesized charcoal, machine-made charcoal, and essential oils. The Group owns natural forest concessions and cutting rights for exploiting timbers on parcels of land in Peru. The Group is organized into two operating divisions; Direct Purchase and Original Design Manufacturer (ODM) Services, and Manufacturing segments. The Direct Purchase and ODM Segment that derives the majority of revenue engages in the business of sourcing live wood and owning designed designs on wood products for sales to end customers.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.